# Hanmi Pharmaceutical obesity drug development > Live situation record from CLSTR: https://clstr.news/situations/hanmi-pharmaceutical-obesity-drug-development > Updated: 2026-08-25T07:34:13.000Z. Sources: 13. Developments: 2. Hanmi Pharmaceutical is advancing its obesity and metabolic disease drug pipeline through both international licensing and domestic development. In late August 2026, Hanmi entered an exclusive licensing agreement with Genentech, a subsidiary of the Roche Group, valued at up to $2.3 billion. The deal covers the drug candidate HM17321, a non-incretin Urocortin-2 (UCN2) analog designed to target obesity, type 2 diabetes, and cardiovascular diseases. Genentech will hold exclusive rights to develop and commercialize the candidate globally, excluding South Korea, once Hanmi completes ongoing Phase 1 clinical trials. Concurrently, Hanmi is preparing for the release of ‘Epe’ (efpeglenatide), South Korea’s first domestic GLP-1 obesity drug, scheduled for the second half of 2026. To chronicle the development of this drug, the company is producing a documentary titled ‘H. O. P (Hanmi Obesity Pipeline)’. The film will detail how Hanmi utilized its proprietary ‘LAPSCOVERY’ platform to continue development after rights were returned following a change in a global partner’s business strategy. ## Timeline ### 2026-08-25: Hanmi Pharmaceutical to produce documentary on obesity drug Epe Hanmi Pharmaceutical is producing a documentary about the development of ‘Epe’, South Korea’s first domestic GLP-1 obesity drug, slated for release later this year. 2 sources. https://clstr.news/cluster/hanmi-pharmaceutical-to-produce-documentary-on-obesity-drug-epe ### 2026-08-24: Hanmi Pharmaceutical signs $2.3 billion obesity drug deal with Genentech Hanmi Pharmaceutical signed a deal worth up to $2.3 billion with Genentech to license its obesity drug candidate HM17321, which aims to reduce weight while preserving muscle mass. 13 sources. https://clstr.news/cluster/hanmi-pharmaceutical-signs-23-billion-obesity-drug-deal-with-genentech --- Cite as: Hanmi Pharmaceutical obesity drug development. CLSTR, https://clstr.news/situations/hanmi-pharmaceutical-obesity-drug-development